Across TCGA pan-cancer cohorts, TRBV19 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRBV19 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TRBV19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRBV19 expression acts as an unfavorable survival marker.

CESC, BLCA, and KIRC are the cancer types where TRBV19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.132	0.875	<.001	24	view →
BLCA	OS	Median	All	0.080	0.720	<.001	24	view →
KIRC	OS	Median	All	0.167	0.655	.038	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRBV19 tumor-vs-normal RNA expression · all TRBV19 data types